Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial

Bartolome R Celli,1 Julie A Anderson,2 Robert Brook,3 Peter Calverley,4 Nicholas J Cowans,5,6 Courtney Crim,7 Ian Dixon,5,6 Victor Kim,8 Fernando J Martinez,9 Andrea Morris,7 David E Newby,10 Julie Yates,7 Joergen Vestbo11

ABSTRACT

Rationale  Systemic levels of C reactive protein (CRP), surfactant protein D (SPD), fibrinogen, soluble receptor of activated glycogen end-product (sRAGE) and club cell protein 16 (CC-16) have been associated with chronic obstructive pulmonary disease (COPD) outcomes. However, they require validation in different cohorts.

Objectives  Relate systemic levels of those proteins to forced expiratory volume in 1 s (FEV1) decline, exacerbations, hospitalisations and mortality in COPD patients (FEV1, of ≥50 and ≤70% predicted) and heightened cardiovascular risk in a substudy of the Study to Understand Mortality and MorbidITy trial.

Methods  Participants were randomised to daily inhalations of placebo, vilanterol 25 μg (VI), fluticasone furoate 100 μg (FF) or their combination (VI 25/FF 100) and followed quarterly until 1000 deaths in the overall 16,485 participants occurred. Biomarker blood samples were available from 1673 patients. The FEV1, decline (mL/year), COPD exacerbations, hospitalisations and death were determined. Associations between biomarker levels and outcomes were adjusted by age and gender.

Results  Systemic levels of CC-16, CRP, sRAGE, SPD and fibrinogen did not relate to baseline FEV1, FEV1 decline, exacerbations or hospitalisations. Fibrinogen and CRP were related to mortality over a median follow-up of 2.3 years. Only the CC-16 changed with study therapy (VI, FF and FF/VI p<0.01) at 3 months.

Conclusions  In COPD, systemic levels of CC-16, CRP, sRAGE, SPD and fibrinogen were not associated with FEV1 decline, exacerbations or hospitalisations. These results cast doubts about the clinical usefulness of the systemic levels of these proteins as surrogate markers of COPD outcomes.

Trial registration number  NCT01313676.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and mortality worldwide.1 Accurate prediction of outcomes such as rate of lung function decline, exacerbations, healthcare utilisation of resources and risk of death are
important because it helps identify patients in whom the implementation of therapeutic measures could improve those outcomes. COPD is also a complex and heterogeneous disease at the genetic, cellular and molecular level, and therefore, it is likely that the use of biomarkers that reflect diverse pathological pathways could help assess multiple dimensions of disease progression that could be modulated with specific therapeutic agents.

Several systemic biomarkers, including C reactive protein (CRP), fibrinogen and surfactant protein D (SPD) have been associated with increased risk of death in patients with COPD. However, their relationship to other outcomes such as rate of decline of the forced expiratory volume in 1 s (FEV₁) of a forced expiratory manoeuvre, exacerbations and hospitalisations remains unclear. The serum concentration of club cell protein 16 (CC-16) was inversely related to rate of FEV₁ decline in observational studies, in pharmacological trials of patients with COPD and in smokers without clinical airflow limitation. The serum levels of soluble receptor of activated glycogen end-product (sRAGE) relate inversely to progression of emphysema, as determined by serially repeated CT of the lungs. In addition, genome-wide association studies (GWAS) do support the increased prevalence of single nucleotide polymorphisms associated to the RAGE, SPD and CC-16 genes. Importantly, the systemic baseline levels of troponin determined in the patients participating in the biomarker component of the Study to Understand Mortality and MorbidITy (SUMMIT) trial were highly predictive of subsequent cardiovascular (CV) events and death in this cohort.

Based on these findings, we hypothesised that the serum levels of one or more of CC-16, CRP, sRAGE, SPD and fibrinogen would relate to the following outcomes: rate of FEV₁ decline, exacerbations of COPD, hospitalisations due to these episodes and the risk of death in patients with COPD. We tested this hypothesis using data and biological samples prospectively collected in the subset of patients recruited in the USA who participated in the SUMMIT study. SUMMIT was an event-driven study that assessed the efficacy and safety of inhaled corticosteroids (ICSs) and long-acting beta agonists (LABA) in COPD patients with heightened CV risk. In the subset of patients, serum samples were taken at baseline and 3 months after randomisation, enabling us to also test whether pharmacotherapy modulated the serum levels of these biomarkers.

**METHODS**

**Study design and study population**

SUMMIT was a prospective, multicentre, international randomised controlled trial to determine whether treatment with the inhaled LABA vilanterol (VI), the ICS fluticasone furoate (FF) or both in combination could improve clinical outcomes in patients with moderate COPD and increased CV risk. Details regarding study design and its primary results have been previously published. In brief, participants included former or current smokers (≥10 pack-years) between 40 and 80 years of age, with a history of COPD and a postbronchodilator FEV₁ to forced vital capacity ≤0.70 and an FEV₁ ≥70% and ≤70% of predicted. They had a score ≥2 on the modified Medical Research Council dyspnoea scale. Patients were additionally required to have a history, or be at increased risk, of CV disease defined as coronary artery or peripheral arterial disease, prior stroke or myocardial infarction, or diabetes mellitus with target organ disease. Patients were also included if they had increased CV risk defined as being ≥60 years and receiving medications for two or more of the following: hypercholesterolaemia, hypertension, diabetes mellitus or peripheral vascular disease. While ICSs and LABA treatments were discontinued before study entry, other COPD medications were permitted during the trial. Participants were randomly allocated to one of four treatments: placebo, FF (100 μg), VI (25 μg) or their combination (FF/VI, 100/25 μg) inhaled once daily as a dry powder. Of the total of 16 485 patients who participated in SUMMIT, 1673 of those enrolled in the USA had blood samples analysed for this biomarker substudy. All patients provided written informed consent. The study is registered on ClinicalTrials.gov.

**Patient and public involvement**

Patients were not involved in the design, conduct or interpretation of the study.

**Measurements and endpoints**

On-treatment spirometry was performed following the European Respiratory Society/American Thoracic Society guidelines. Spirometric reference values were those of National Health and Nutrition Examination Survey. On-treatment COPD exacerbations requiring treatment with antibiotics and/or oral corticosteroids were recorded as moderate exacerbations, and those requiring hospitalisation were recorded as severe. On-treatment and post-treatment deaths were adjudicated for cause by an endpoint committee.

**Biomarkers**

Blood samples were collected at baseline and 3 months postrandomisation. Samples were stored at –80°C until analysed. SPD, CC-16 and sRAGE were measured in serum samples. Fibrinogen and CRP (high-sensitivity
methods) were measured in plasma samples. All protein biomarkers were measured by validated immunoassays. Concentrations below lower limit of detection (LLD) were imputed to $\frac{1}{2} \times \text{LLD}$.

Statistical analysis
To examine the effect of treatment on the change in biomarker concentrations between baseline and 3 months, analyses of covariance were performed using the covariates of baseline biomarker concentration, age and gender. As all biomarkers except fibrinogen had positively skewed distributions, these were log transformed, and the changes were expressed as ratios, and geometric means presented rather than arithmetic means.

The biomarker concentrations were divided into groups according to tertiles at baseline and are presented in online supplementary table 1. To explore whether the biomarker concentrations affected rate of decline in FEV$_1$, random coefficients models were fitted with terms of age, gender, baseline FEV$_1$, time, treatment, treatment by time, baseline biomarker tertile groups and baseline biomarker tertile groups by time, with subjects fitted as a random effect. Associations between baseline biomarker tertile groups and endpoints including all-cause mortality, CV death, moderate or severe exacerbations and severe exacerbations were modelled using Cox proportional hazards including terms for age, gender and study treatment and also previous exacerbation history for the exacerbation endpoints.

Correlations between variables of interest were explored using Pearson’s correlation coefficient.

Two-sided tests were performed post hoc at the 0.05 level of significance, using SAS V.9.4. All $p$ values are nominal, as no adjustment was made for multiple comparisons.

RESULTS
Clinical data
The published primary results of SUMMIT showed that there was no effect of any of the therapies on mortality, the primary outcome. The Consolidated Standards of Reporting Trials diagram of the SUMMIT systemic biomarker substudy enrolled in the USA is shown in figure 1. Of the 16,485 worldwide patients participating in SUMMIT, 1,673 recruited in the USA had biomarker data at baseline.

The clinical characteristics of the patients included in the study and those from the general SUMMIT population are shown in table 1. Most characteristics were similar in both groups, except for the biomarker population having more females, higher body mass index, fewer COPD exacerbations in the year prior to the study and some differences in CV history and CV therapy. In the biomarker substudy, the average age was 66 years, 62% of the patients were male and 49% were smoking at the time of enrolment. By design, they had moderate airflow limitation by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (FEV$_1$, 60% predicted) and had significant CV disease or risk. Patients were followed for mortality for a median of 2 years and 3 months and for all on-treatment endpoints for a median of 18 months and an average of seven spirometric measurements over this time.

Effect of treatment on biomarker concentration at 3 months
Inhaled VI, FF and the combination resulted in a 6%–9% reduction in CC-16 serum levels as is shown in online supplementary table 2 ($p<0.01$ for all three compared with placebo). However, there was no effect of the inhaled therapy on systemic levels of CRP, sRAGE, SPD and fibrinogen when compared with placebo (online supplementary table 3).
Table 1  Demographic characteristics of the patients included in the biomarker substudy conducted in the USA and that of the worldwide participants

<table>
<thead>
<tr>
<th>Biomarker substudy</th>
<th>SUMMIT population</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=1673</td>
<td>n=16 485</td>
</tr>
<tr>
<td>Age, years</td>
<td>66 (8)</td>
</tr>
<tr>
<td>Women</td>
<td>635 (38%)</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>31 (7)</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>828 (49%)</td>
</tr>
<tr>
<td>Smoking history (pack-years)</td>
<td>52 (29)</td>
</tr>
<tr>
<td>Respiratory status</td>
<td></td>
</tr>
<tr>
<td>Postbronchodilator FEV₁ (L)</td>
<td>1.7 (0.4)</td>
</tr>
<tr>
<td>Predicted postbronchodilator FEV₁ (%)</td>
<td>59 (7)</td>
</tr>
<tr>
<td>Exacerbations in 12 months before study</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>1215 (73%)</td>
</tr>
<tr>
<td>1</td>
<td>290 (17%)</td>
</tr>
<tr>
<td>2+</td>
<td>168 (10%)</td>
</tr>
<tr>
<td>Cardiovascular inclusion criteria</td>
<td></td>
</tr>
<tr>
<td>Manifest disease</td>
<td></td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>818 (49%)</td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
<td>384 (23%)</td>
</tr>
<tr>
<td>Previous stroke</td>
<td>172 (10%)</td>
</tr>
<tr>
<td>Previous myocardial infarction</td>
<td>413 (25%)</td>
</tr>
<tr>
<td>Diabetes with target organ disease</td>
<td>226 (14%)</td>
</tr>
<tr>
<td>At risk</td>
<td></td>
</tr>
<tr>
<td>Hypercholesterolaemia</td>
<td>1072 (64%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1166 (70%)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>447 (27%)</td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
<td>106 (6%)</td>
</tr>
<tr>
<td>Concomitant medications</td>
<td></td>
</tr>
<tr>
<td>Antiplatelet</td>
<td>1081 (65%)</td>
</tr>
<tr>
<td>Beta-blocker</td>
<td>787 (47%)</td>
</tr>
<tr>
<td>ACE inhibitor</td>
<td>779 (47%)</td>
</tr>
<tr>
<td>Statin</td>
<td>2623 (75%)</td>
</tr>
<tr>
<td>Long-acting muscarinic antagonist</td>
<td>168 (10%)</td>
</tr>
<tr>
<td>Xanthine (including theophylline)</td>
<td>78 (5%)</td>
</tr>
<tr>
<td>Treatment allocation</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>439 (26%)</td>
</tr>
<tr>
<td>Fluticasone furoate</td>
<td>415 (25%)</td>
</tr>
<tr>
<td>Vilaferon</td>
<td>416 (25%)</td>
</tr>
<tr>
<td>Combination therapy</td>
<td>403 (24%)</td>
</tr>
</tbody>
</table>

Continuous variables are mean (SD); categorical variables are n and (%).

BMI, body mass index; FEV₁, forced expiratory volume in 1 s; SPD, surfactant protein D; sRAGE, soluble receptor of activated glycogen end-product.

Baseline biomarker data and outcomes

There was no relationship between baseline levels of CC-16, CRP, sRAGE, SPD and fibrinogen and baseline FEV₁ expressed as % of predicted normal value (figure 2). The rate of decline in FEV₁ was not different between the baseline tertile groups for any of the biomarkers (table 2). There was no association between any of the biomarker concentrations and the risk of a moderate or severe COPD exacerbation (online supplementary figure 1) or a hospitalised exacerbation (online supplementary figure 2).

Higher systemic levels of CRP and fibrinogen were associated with higher risk of all-cause mortality as is shown in figure 3. The number of deaths by any cause for CRP were: highest tertile group 36 (7%) versus lowest tertile group 22 (4%), HR 1.91; middle tertile group 35 (6%) versus lowest tertile group 22 (4%), HR 1.70; for fibrinogen they were highest group 43 (8%) versus lowest group 21 (4%), HR 2.24; middle group 24 (5%) versus lowest group 21 (4%), HR 1.24. There were no apparent relationships between CC-16, sRAGE and SPD and all-cause mortality (online supplementary figure 3) or with any of the measured biomarkers and CV death (online supplementary figure 4).

DISCUSSION

This prospective study of COPD patients with moderate airflow limitation and heightened CV risk provides two novel findings. First, the systemic levels of the five cytokines (CC-16, sRAGE, SPD, CRP and fibrinogen S), selected because of previous studies suggesting their potential value as predictors of outcomes in COPD, were unrelated to rate of FEV₁ decline, exacerbation frequency and hospitalisations in these patients. The systemic levels of CRP and fibrinogen were associated with increased risk of all-cause mortality, confirming the predictive value for this outcome reported by others. Second, compared with placebo, once-daily inhalation of...
### Table 2 Rate of FEV₁ decline (mL/year) by systemic biomarker tertile groups

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Number of patients in analysis*</th>
<th>Lowest tertile group</th>
<th>Middle tertile group</th>
<th>Highest tertile group</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP†</td>
<td>1462</td>
<td>−38 (7)</td>
<td>−40 (7)</td>
<td>−33 (7)</td>
</tr>
<tr>
<td>sRAGE†</td>
<td>1454</td>
<td>−37 (7)</td>
<td>−37 (7)</td>
<td>−36 (7)</td>
</tr>
<tr>
<td>SPD†</td>
<td>1461</td>
<td>−30 (7)</td>
<td>−33 (7)</td>
<td>−48 (7)</td>
</tr>
<tr>
<td>Fibrinogen†</td>
<td>1410</td>
<td>−39 (7)</td>
<td>−35 (7)</td>
<td>−37 (8)</td>
</tr>
</tbody>
</table>

**CC-16:**

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Number of patients in analysis*</th>
<th>Mean rate of decline (mL/year) (SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>365</td>
<td>33 (15)</td>
</tr>
<tr>
<td>FF 100</td>
<td>362</td>
<td>32 (15)</td>
</tr>
<tr>
<td>VI 25</td>
<td>363</td>
<td>62 (15)</td>
</tr>
<tr>
<td>FF/VI 100/25</td>
<td>371</td>
<td>27 (15)</td>
</tr>
</tbody>
</table>

**CC-16,** club cell protein 16; **CRP,** C reactive protein; **FEV₁,** forced expiratory volume in 1 s; **FF,** fluticasone furoate; **SPD,** surfactant protein D; **sRAGE,** soluble receptor of activated glycogen end-product; **VI,** vilanterol.

*To be included in the analysis a patient needed to have an on-treatment FEV₁ measurement and the baseline biomarker measurement.

†All four treatment arms (placebo, FF, VI and FF/VI): random coefficients model fitted with terms of age, gender, baseline FEV₁, time, treatment, treatment by time, baseline biomarker tertile groups and baseline biomarker tertile groups by time.

‡Presented by arm, because CC-16 concentrations at 3 months were affected by treatment (online supplementary tables S2): random coefficients model fitted with terms of age, gender, baseline FEV₁, time, baseline CC-16 tertile groups and baseline CC-16 tertile groups by time.

Previous studies

There has been a growing interest in the field of biomarkers in COPD as a tool to predict outcomes or as marker of them, thus making them theoretically useful as surrogate markers of response for therapeutic interventions.⁹¹⁰₂¹⁻²³ CRP has been the best studied biomarker in COPD. Most studies found that CRP levels are elevated in these patients,⁶²⁴⁻²⁵ as compared with non-smokers and smokers without airflow obstruction, but the relationship between CRP levels and exacerbations as well as mortality remain inconsistent.²⁵⁻²⁶ Studies have also not consistently shown a relationship between CRP and rate of lung function decline.¹¹ Similarly, several studies have documented a relationship between blood levels of fibrinogen and risk of death in patients in general and COPD in particular.⁵⁷⁻²⁸ Integration of all the data available by the COPD Biomarker Qualification Consortium initiative resulted in US Food and Drug Administration approval of this biomarker to stratify patients for studies of COPD.⁷ There is less information regarding the relationship between systemic levels of fibrinogen and other important outcomes in COPD, such as rate of lung function decline and hospitalisations.²⁹

Of the many other systemic biomarkers studied in patients with COPD, the circulating levels of CC-16, SPD and sRAGE have shown the strongest association between their levels and COPD outcomes.¹⁵⁻³⁰⁻³⁴ CC-16 levels have been found to be reduced in patients with COPD and are inversely associated with rate of decline of FEV₁ in some studies.¹³⁻³⁵ The lung-derived protein SPD, however, is associated with presence of pulmonary inflammation and is elevated in smokers with or without COPD.³¹ The
systemic levels of sRAGE are inversely related to the degree of emphysema as determined by CT scans of the lungs, while GWAS have documented the increased prevalence of single nucleotide polymorphisms associated with the RAGE gene. All of these proteins have been suggested as potential biomarkers of COPD outcomes, but not all of them have been studied simultaneously and prospectively while evaluating the effect of therapy on their levels.

Although statistically significant associations are important for studies and research, the ideal biomarker for the clinician is useful primarily if it helps a single patient, the one in front of the provider. So if a biomarker is to reach the bedside, it has to have a strong association with an outcome and provide information above and beyond that obtained by good clinical evaluation.

Current findings

The prospective SUMMIT study provided the opportunity to test the predictive ability of the selected circulating proteins on important respiratory outcomes. To our disappointment, none of the systemic levels of the five circulating proteins studied related to rate of FEV₁ decline, exacerbations and hospitalisations (table 2, online supplementary figures 1 and 2). Although a true association might have been found if more patients had been recruited, this appears unlikely as several of the studies documenting an association between those biomarkers and the outcomes were smaller or similar in size to ours. In addition, it is known that the rate of FEV₁ decline is larger in patients with higher FEV₁, so if there was a relationship between any of the biomarkers selected and lung function decline, these moderately obstructed patients were the most likely individuals to have demonstrated such an association. Furthermore, a biomarker is most useful when it can help clinicians in their practice usually with a single patient, and certainly, the lack of precision documented in this study renders them of limited use in everyday patient care. However, the association observed between systemic levels of CRP and fibrinogen with mortality in this study (figure 3) supports their validity as predictors of risk of death in general and in patients with heightened CV risk, as were those included in SUMMIT. We acknowledge that there were no measurements of these biomarkers during exacerbations, where the changes might identify or grade the severity of these events, as has been suggested before. Importantly, the significant association observed between baseline serum levels of troponin and subsequent risk of CV events and death in this cohort indicates that methodological issues or the study design and completion are unlikely to have influenced the results here reported.

The difference between the negative results in COPD-related outcomes in this study, and the positive ones reported by previous authors may relate primarily to the populations included in the different studies. Whereas the majority of the positive results came from cohort studies such as ECLIPSE and COPDgene, which included patients with a wider range of lung function impairment, the population included in SUMMIT consisted of patients with a moderate degree of airflow limitation and heightened CV risk. However, for a biomarker to be useful in clinical practice, it has to help clinicians at any stage of the disease and most of all for patients with milder disease, such as those included in SUMMIT.

One potential use of biomarkers is their response to therapy specifically directed at the disease in question and if this change was associated to a modification in outcomes. In this study, the relative levels of CC-16 were decreased by the three active treatment arms of the study compared with placebo. The effects were small, likely of little clinical meaning, but nevertheless statistically significant (table S2). A decrease in CC-16 was not associated with FEV₁ decline in this study, a fact that could have several explanations. First, that CC-16 bears little relation to FEV₁ decline, as has been suggested by some studies, or second, that the small changes in serum levels of CC-16 carry little biological significance. However, the results do suggest that inhaled therapies may alter systemic levels of cytokines and that if associations with valid outcomes were to be found, one or more cytokines could be used as surrogate markers to evaluate effect of therapy. Interestingly, we found no effect of any of the therapies given in SUMMIT on CRP levels, providing contrast to the findings of an older study that demonstrated reduced CRP levels after the administration of ICSs. Conversely, however, our findings are in agreement with those of a further study, in which the administration of inhaled tiotropium did not affect inflammatory markers in patients with COPD. Finally, the stability of the selected biomarkers over 3 months is consistent with data previously reported in ECLIPSE.
Conclusions
In this substudy of the SUMMIT trial of patients with moderate COPD, the serum level of CC-16, sRAGE, and SPD or their changes over 3 months were not predictive of rate of lung function decline and risk of exacerbations or hospitalisations. Although systemic levels of CRP and fibrinogen were associated with increased mortality risk, the levels were not associated with rate of FEV$_1$ decline, exacerbations or hospitalisations. These results cast some doubts about the clinical usefulness of the systemic levels of CC-16, sRAGE and SPD as surrogate markers of disease in patients with moderate COPD.

Author affiliations
1Pulmonary and Critical Care Division, Brigham and Women’s Hospital, Boston, Massachusetts, USA
2Research & Development, GlaxoSmithKline Plc Stockley Park, Uxbridge, , UK
3Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA
4Department of Medicine, Clinical Sciences Centre, University of Liverpool, University Hospital Aintree, Liverpool, , UK
5GlaxoSmithKline Plc Stockley Park, Uxbridge, , UK
6Veramed Ltd, Twickenham, UK
7GlaxoSmithKline Research Triangle Park, Research Triangle Park, North Carolina, USA
8Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania, USA
9Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine Samuel J Wood Library, New York City, New York, USA
10British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, , UK
11Division of Infection, Immunity and Respiratory Medicine and Allergy, Manchester Academic Health Science Centre, The University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK

Acknowledgements
Editorial assistance was provided by Matthew Hallam, MSc, and Carol A Richter, PhD, at Gardiner-Caldwell Communications (Macclesfield) and was funded by GlaxoSmithKline plc.

Contributors
Study design: BCR, JAA, RB, PC, CC, ID, FJM, DEN, DY and JY. Data collection: JAA, CC, NJC and JV. Database search: N/A. Data analysis/interpretation: BCR, JAA, RB, PC, NJC, CC, ID, VK, FJM, AM, DEN, DY and JY. Writing/reviewing of the manuscript: BCR, JAA, RB, PC, NJC, CC, ID, VK, FJM, AM, DEN, DY and JY. Final approval of the manuscript: all authors.

Funding
This work was supported by GlaxoSmithKline plc.

Competing interests
None declared.

Patient consent for publication
Not required.

Ethics approval
All patients provided written informed consent. The study was approved by local ethics committees and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Members of the Steering Committee Jørgen Vestbo (cochair, UK), Robert Brook (USA), Peter Calverley (UK), Bartolome Celli (USA), Fernando Martinez (USA), David Newby (UK), Courtney Crim (cochair, GlaxoSmithKline plc, USA), Julie Anderson (GlaxoSmithKline plc, UK) and Julie Yates (GlaxoSmithKline plc, USA). Members of the Independent Data Monitoring Committee Peter Lange (chair, Denmark), Richard Kay (UK), Mark Dransfield (USA) and Sanjay Rajagopal (USA). Members of the Clinical Endpoint Committee Robert Wise (chair, USA), Dennis Niewboer (USA), Camilo Gomez (USA), Sheldon Madger (Canada), Martin Denis (UK) and Pierre Amarancico (France).

Provenance and peer review
Not commissioned; internally peer reviewed.

Data availability statement
Information on GSK’s data sharing commitments and access to anonymised individual participant data and associated documents can be found at www.clinicalstudydatarequest.com

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES